Neutralising antibodies after infection and vaccination, living with children and the risk of COVID-19, vaccine second-dose completion in the US

Peer reviewed journals featured:

- A narrative review on SARS-CoV-2 variants, immune responses and neutralisation-resistance [here](#)
- Modelling studies on:
  - SARS-CoV-2 vaccination alongside physical distancing in the UK [here](#) and associated commentary [here](#)
  - Vaccination and non-pharmaceutical interventions for COVID-19 in the UK [here](#)
- A case report on viable SARS-CoV-2, 72 days after infection in an immunocompromised patient [here](#)
- Observational studies on:
  - COVID-19 vaccine second-dose completion and interval between first and second doses in the US [here](#)
  - An association between living with children and outcomes from COVID-19 [here](#)
  - An association between sharing a household with children and the risk of COVID-19 in healthcare worker households in Scotland [here](#)
  - A comparison of COVID-19 policies in aged care homes in Australia and the UK [here](#)
  - An association between vitamin D levels, race/ethnicity, clinical characteristics and COVID-19 test results [here](#)
  - Trends in mortality and length of stay among COVID-19 patients (April – July 2020) in the US [here](#)

Letters and correspondence discussed:

- Neutralising antibodies against SARS-CoV-2 variants after infection and vaccination [here](#)
- A proposal for free licensing of vaccines to end the COVID-19 crisis [here](#)
- Safety of mRNA SARS-CoV-2 vaccines for patients with rheumatic musculoskeletal disease [here](#)
- Early antibody response in kidney transplant recipients after first dose of mRNA vaccine [here](#)
Pre-peer review articles featured:

- The effect of vaccination on transmission of COVID-19 [here](#)
- The indirect health impacts of COVID-19 restrictions [here](#)
- Evidence for antibody as a protective correlate for COVID-19 vaccines [here](#)
- Information about COVID-19 vaccine effectiveness and its impact on behavioural intentions [here](#)
- The risk of reinfection after seroconversion to SARS-CoV-2 [here](#)
- Development and validation of tools to monitor post-acute COVID-19 syndrome [here](#)
- Long-term outcomes in COVID-19 patients associated with neurological complications [here](#)

Guidance and reports

- The Organisation for Economic Cooperation and Development released a report on global access to COVID-19 vaccines [here](#)
- The Australian Technical Advisory Group on Immunisation (ATAGI) released a statement and clinical guidance on AstraZeneca COVID-19 vaccine safety [here](#)
- The Therapeutic Goods Administration (TGA) released updates on AstraZeneca vaccine [here, here](#) and [here](#)

News and blogs

- Stronger warnings are needed to curb socialising after vaccination [here](#)
- Influenza vaccination in 2021 [here](#)
- Lateral flow tests and mass testing in schools in the UK [here](#)
- Sputnik V and other Russian vaccines [here](#)
- Protecting society from pandemics and politicians [here](#)
- Balancing monitoring for adverse events with confidence in vaccines [here](#)
- Increased risk of mortality in patients infected with B.1.1.7 (UK / Kent) variant [here](#)
- The medical establishment ‘is failing the UK public’ on COVID-19 [here](#)

[Click here](#) to subscribe to the daily evidence digest.